An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 2, 2015, Pages 182-189

  Teng, Renli ^a   Carlson, Glenn ^a   Hsia, Judith ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bioequivalence; Drug administration routes; Ticagrelor

Indexed keywords

AR C 124910 XX; DRUG METABOLITE; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TABLET;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NASOGASTRIC DRUG ADMINISTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH INFECTION; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; MIDDLE AGED; TABLET;

ADENOSINE; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TABLETS;

EID: 84922181324     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202202     Document Type: Article

References (23)

1. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27: 1038-1047. CrossRef PubMed
2. VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009; 7: 1556-1565. CrossRef PubMed
3. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007; 50: 1844-1851. CrossRef PubMed
4. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014; 19: 209-219. CrossRef PubMed
5. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013; 61: 723-727. CrossRef PubMed
6. Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects. Can J Clin Pharmacol. 2010; 15: e426.
7. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010; 66: 487-496. Cross-Ref PubMed
8. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120: 2577-2585. CrossRef PubMed
9. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011; 39: 703-710. CrossRef PubMed
10. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057. CrossRef PubMed
11. Food and Drug Administration. Drug Labels: Brilinta prescribing information. http://www.fda. gov/downloads/Drugs/DrugSafety/UCM264220. pdf; accessed February 17 2014.
12. Batty S. Communication, swallowing and feeding in the intensive care unit patient. Nurs Crit Care. 2009; 14: 175-179. CrossRef PubMed
13. Bassi D, Furkim AM, Silva CA, Coelho MS, Rolim MR, de Alencar ML, Machado MJ. Identification of risk groups for oropharyngeal dysphagia in hospitalized patients in a university hospital. Codas. 2014; 26: 17-27. PubMed
14. Wright DJ, Kelly J. Medication administration in patients with dysphagia. Nurs Stand. 2012; 27: 35-40. CrossRef PubMed
15. Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013; 69: 937-948. CrossRef PubMed
16. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010; 70: 65-77. CrossRef PubMed
17. Teng R, Butler K. Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. Int J Clin Pharmacol Ther. 2013; 51: 795-806. CrossRef PubMed
18. Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013; 2: 30-39.
19. Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Drugs R D. 2013; 13: 153-157. CrossRef PubMed
20. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878: 2299-2306. CrossRef PubMed
21. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012; 5: 797-804. Cross-Ref PubMed
22. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in STsegment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013; 61: 1601-1606. CrossRef PubMed
23. Camurça FD, De Queiroz DA, Leal PR, Rodrigues CL, Gondim FA, Da Graça JR, Rola FH, Nobre e Souza MA, dos Santos AA. Gastric emptying and gastrointestinal transit of liquid in awake rats is delayed after acute myocardial infarction. Dig Dis Sci. 2004; 49: 757-762. CrossRef PubMed